February 12, 2021
Article
The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.
October 01, 2020
Article
Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.
September 29, 2020
Article
The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.